Neos Therapeutics at Cantor Fitzgerald Global Healthcare Conference (Live)
09/26/17 at 2:50 p.m. ET
Corporate ProfileNeos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using our proprietary extended-release drug delivery and orally disintegrating tablet (ODT) technology platforms. We have two FDA approved products for the treatment of ADHD and both utilize our extended-release ODT technology. Our third branded ADHD product candidate is an extended-release oral suspension. Our growing ADHD Product Portfolio puts Neos in a unique position to meet the different needs of patients that struggle with ADHD.
- 09/15/17Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older
- 09/05/17Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
- 08/30/17Neos Therapeutics to Participate in Three September Conferences
- 08/08/17Neos Therapeutics Reports Second Quarter 2017 Financial Results